人工智能辅助评估转移性葡萄膜黑色素瘤tebentafusp代谢反应:长轴视野[18F]FDG PET/CT研究
本研究纳入15例接受tebentafusp治疗的转移性葡萄膜黑色素瘤患者,在基线和治疗后3个月行[18F]FDG长轴视野PET/CT,用深度学习分割工具量化TMTV和TLG并按AI辅助PERCIST 1.0评估代谢反应。基线和3个月时较高的TMTV、TLG均与较短总生存期显著相关,疾病控制组总生存期有改善趋势但未达统计学显著。
要点
- AI辅助自动分割在全部15例患者中成功获得TMTV和TLG。
- 基线及3个月后较高的TMTV、TLG均与较短总生存期显著相关(p<0.05)。
- AI辅助PERCIST评估疾病控制6例、进展9例,总生存期改善趋势未达显著(p=0.08)。
核心结论
- AI辅助全身[18F]FDG PET/CT量化及基于PERCIST的反应评估在tebentafusp治疗的转移性葡萄膜黑色素瘤中可行并具有预后意义。
- TMTV和TLG可能作为该恶性肿瘤风险分层和治疗监测的无创影像生物标志物。
研究设计与样本
- 研究纳入15例接受tebentafusp治疗的转移性葡萄膜黑色素瘤患者,在基线和治疗后3个月行[18F]FDG长轴视野PET/CT。
- 使用基于深度学习的分割工具在RECOMIA平台量化总代谢肿瘤体积(TMTV)和总病灶糖酵解(TLG)。
- 按AI辅助PERCIST 1.0标准评估代谢反应,采用Kaplan-Meier生存分析评估PET参数与总生存期的关联。
主要发现
- 中位随访时间(95%CI)为14.1个月(12.9个月至未获得)。
- 基线TMTV升高与较短总生存期显著相关:16.9个月 vs 27.2个月(p<0.05);基线TLG升高与较短总生存期显著相关:16.9个月 vs 27.2个月(p<0.05)。
- 治疗后3个月较高TMTV预测较差生存:14.3个月 vs 24.5个月(p<0.05);较高TLG预测较差生存:14.3个月 vs 24.5个月(p<0.05)。
- AI辅助PERCIST评估显示6例疾病控制(完全代谢反应、部分代谢反应、稳定代谢疾病),9例进展性代谢疾病;疾病控制组总生存期有改善趋势:24.5个月 vs 14.6个月(p=0.08)。
- 8例患者可获取基于GNAQ和GNA11突变的循环肿瘤DNA(ctDNA)水平;tebentafusp治疗3个月后5例ctDNA水平降低或稳定,3例升高(中位总生存期:24.5个月 vs 3.3个月;p=0.13);ctDNA升高患者随访影像上TMTV和TLG显著更高。
关键数值与推荐
- 代谢反应按AI辅助PERCIST 1.0标准评估,疾病控制包括完全代谢反应、部分代谢反应和稳定代谢疾病。
- TMTV和TLG通过RECOMIA平台上基于深度学习的分割工具自动量化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Tebentafusp has emerged as the first systemic therapy to significantly prolong survival in treatment-naïve HLA-A*02:01 + patients with unresectable or metastatic uveal melanoma (mUM). Notably, a survival benefit has been observed even in the absence of radiographic response. This study aims to investigate the feasibility and prognostic value of artificial intelligence (AI)-assisted quantification and metabolic response assessment of [18F]FDG long axial field-of-view (LAFOV) PET/CT in mUM patients undergoing tebentafusp therapy. MATERIALS AND METHODS: Fifteen patients with mUM treated with tebentafusp underwent [18F]FDG LAFOV PET/CT at baseline and 3 months post-treatment. Total metabolic tumor volume (TMTV) and total lesion glycolysis (TLG) were quantified using a deep learning-based segmentation tool On the RECOMIA platform. Metabolic response was assessed according to AI-assisted PERCIST 1.0 criteria. Associations between PET-derived parameters and overall survival (OS) were evaluated using Kaplan-Meier survival analysis. RESULTS: The median follow up (95% CI) was 14.1 months (12.9 months - not available). Automated TMTV and TLG measurements were successfully obtained in all patients. Elevated baseline TMTV and TLG were significantly associated with shorter OS (TMTV: 16.9 vs. 27.2 months; TLG: 16.9 vs. 27.2 months; p < 0.05). Similarly, higher TMTV and TLG at 3 months post-treatment predicted poorer survival outcomes (TMTV: 14.3 vs. 24.5 months; TLG: 14.3 vs. 24.5 months; p < 0.05). AI-assisted PERCIST response evaluation identified six patients with disease control (complete metabolic response, partial metabolic response, stable metabolic disease) and nine with progressive metabolic disease. A trend toward improved OS was observed in patients with disease control (24.5 vs. 14.6 months, p = 0.08). Circulating tumor DNA (ctDNA) levels based on GNAQ and GNA11 mutations were available in 8 patients; after 3 months Of tebentafusp treatment, 5 showed reduced Or stable ctDNA levels, and 3 showed an increase (median OS: 24.5 vs. 3.3 months; p = 0.13). Patients with increasing ctDNA levels exhibited significantly higher TMTV and TLG on follow-up imaging. CONCLUSION: AI-assisted whole-body quantification of [1⁸F]FDG PET/CT and PERCIST-based response assessment are feasible and hold prognostic significance in tebentafusp-treated mUM. TMTV and TLG may serve as non-invasive imaging biomarkers for risk stratification and treatment monitoring in this malignancy.
引用
- Sachpekidis C, Machiraju D, Strauss DS, et al. Artificial intelligence-assisted assessment of metabolic response to tebentafusp in metastatic uveal melanoma: a long axial field-of-view [18F]FDG PET/CT study. Eur J Nucl Med Mol Imaging. 2025. PMID: 40913640. doi:10.1007/s00259-025-07504-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。